Literature DB >> 30391234

Diabesity and antidiabetic drugs.

Joseph M Pappachan1, Cornelius J Fernandez2, Elias C Chacko3.   

Abstract

The prevalence of "diabesity" - diabetes related to obesity - has increased tremendously over the past few decades because of the global obesity epidemic. Although bariatric surgery is the best treatment option for patients with diabesity, a majority of patients are managed only with antidiabetic drugs for various reasons. Diabetes control with antidiabetic agents may affect diabesity outcomes positively or negatively because of their effects on body weight and other metabolic parameters. For this reason, rational use of anti-diabetic medications is imperative to optimise long-term management of diabesity. Understanding the molecular mechanisms of antidiabetic drugs and/or drug combinations on diabesity outcomes are therefore important not only for the basic scientists but also for clinicians. This review explores the molecular signalling cascades of antidiabetic medications in the management of diabesity.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antidiabetic drug combination; Antidiabetic drugs; Contents; Diabesity; Medical management of diabesity

Mesh:

Substances:

Year:  2018        PMID: 30391234     DOI: 10.1016/j.mam.2018.10.004

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  7 in total

1.  Blood Lead Level Is Associated with Visceral Adipose Dysfunction in Patients with Type 2 Diabetes.

Authors:  Chi Chen; Bin Wang; Haojie Zhang; Yuying Wang; Shiyan Yu; Shuo Zhou; Yi Chen; Fangzhen Xia; Hualing Zhai; Ningjian Wang; Yingli Lu
Journal:  Biol Trace Elem Res       Date:  2022-07-18       Impact factor: 4.081

2.  Ethyl Gallate Dual-Targeting PTPN6 and PPARγ Shows Anti-Diabetic and Anti-Obese Effects.

Authors:  Dohee Ahn; Jinsoo Kim; Gibeom Nam; Xiaodi Zhao; Jihee Kwon; Ji Young Hwang; Jae Kwan Kim; Sun-Young Yoon; Sang J Chung
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

Review 3.  Type 2 diabetes - unmet need, unresolved pathogenesis, mTORC1-centric paradigm.

Authors:  Jacob Bar-Tana
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 4.  Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales.

Authors:  Amelia D Dahlén; Giovanna Dashi; Ivan Maslov; Misty M Attwood; Jörgen Jonsson; Vladimir Trukhan; Helgi B Schiöth
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

5.  Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes.

Authors:  Guoxia Ji; Qinghua Guo; Qidi Xue; Ruifang Kong; Shiben Wang; Kang Lei; Renmin Liu; Xuekun Wang
Journal:  Molecules       Date:  2021-11-16       Impact factor: 4.411

6.  Structure-Activity Relationship of Synthetic Ginkgolic Acid Analogs for Treating Type 2 Diabetes by PTPN9 Inhibition.

Authors:  Jinsoo Kim; Jinyoung Son; Dohee Ahn; Gibeom Nam; Xiaodi Zhao; Hyuna Park; Woojoo Jeong; Sang J Chung
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

7.  Discovery of the First in Class 9-N-Berberine Derivative as Hypoglycemic Agent with Extra-Strong Action.

Authors:  Mikhail V Khvostov; Elizaveta D Gladkova; Sergey A Borisov; Nataliya A Zhukova; Mariya K Marenina; Yuliya V Meshkova; Olga A Luzina; Tatijana G Tolstikova; Nariman F Salakhutdinov
Journal:  Pharmaceutics       Date:  2021-12-12       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.